Elicera Therapeutics AB
F:8E8
Elicera Therapeutics AB
F:8E8
Price:
0.2335
EUR
-2.91%
Market Closed
Market Cap:
€8.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Elicera Therapeutics AB
F:8E8
|
SE |
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| 11.6m | 52.4m | 43.8m | 29.4m | 26.4m | 24.8m | |
| 11.6m | 52.4m | 43.8m | 29.4m | 26.4m | 24.8m | |
| 445.7k | 204.3k | 2m | 784.3k | 1.2m | 545.9k | |
| 49k | 1.6m | 0 | — | — | 2m | |
| 12.1m | 54.2m | 45.8m | 30.2m | 27.6m | 27.4m | |
| 47.1k | 35.3k | 23.6k | 11.8k | 0 | 0 | |
| 483.2k | 484.2k | 484.2k | 1k | 1k | 0 | |
| — | — | 0 | — | — | — | |
| 12.6m | 54.7m | 46.3m | 30.2m | 27.6m | 27.4m | |
| 2m | 2m | 731.9k | 883k | 2m | 2.6m | |
| 294.6k | 309.9k | 12.5m | 12.5m | 4.4m | 1.2m | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 107.1k | 142.1k | 242k | 399.5k | 354.4k | 249k | |
| 2.4m | 2.5m | 13.5m | 13.8m | 6.8m | 4.1m | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 2.4m | 2.5m | 13.5m | 13.8m | 6.8m | 4.1m | |
| 505.3k | 830.8k | 830.8k | 830.8k | 1.5m | 2m | |
| (2.3m) | (15.4m) | (34.8m) | (51.2m) | (67.3m) | (84.7m) | |
| 12m | 66.8m | 66.8m | 61.8m | 86.6m | 106.1m | |
| — | 0 | 0 | 5m | — | — | |
| 10.2m | 52.2m | 32.8m | 16.4m | 20.8m | 23.4m | |
| 12.6m | 54.7m | 46.3m | 30.2m | 27.6m | 27.4m | |
| 19.8m | 19.8m | 19.8m | 20.3m | 36m | 49.8m |
A growing testing platform nearing break-even but still reliant on external funding
A pre-revenue clinical biotech funding rising trial costs through external capital
A rapidly scaled RNAi platform moving from R&D losses to product profitability
A cash-generative biotech transitioning from legacy MS to acquired growth platforms
Continue Research
Other Elicera Therapeutics AB listings: